Page 37 - Read Online
P. 37
Page 988 Lee et al. Cancer Drug Resist 2020;3:980-91 I http://dx.doi.org/10.20517/cdr.2020.73
Figure 7. Co-exposure of erlotinib and prexasertib significantly reduced tumor progression in MDA-231 and MDA-468 xenografts. MDA-
231 and MDA-468 xenograft containing mice were treated with vehicle, 10 mg/kg BW prexasertib, 50 mg/kg BW erlotinib, or both
prexasertib and erlotinib (A); tumor weights at sacrifice for MDA-231 and MDA-468 (B)
Figure 8. Immunoblotting of MDA-468 xenografts. MDA-468 xenograft tumors were excised and examined for the indicated protein
expression. Three tumors per group were analyzed. AKT: protein kinase B; EGFR: epidermal growth factor receptor
